James Emanuel of Rock & Turner presented his thesis on Craneware (UK: CRW) at European Investing Summit 2026.
Thesis summary:
Craneware is a Scotland-headquartered, London-listed provider of mission-critical US healthcare SaaS, with all of its customers in the US. Founded in 1999 and listed in 2006, it is still run by its founder-CEO, who owns about 9.5%; insiders hold 31%. Its Trisus platform helps hospitals document, code and bill against complex Medicare, Medicaid and private payer rules. After a 2021 acquisition, it serves more than 12,000 hospitals, clinics and pharmacies, about 40% of the US hospital market.
James calls Craneware a capital-light compounder with about 90% gross margins, over 90% recurring revenue and net cash. The company estimates that hospitals save $5 for every $1 spent, so the software’s net cost is negative, and stopping it costs more than keeping it. Its ten largest customers have stayed an average of 21 years, yet the largest accounts for under 8% of ARR. Net revenue retention hovers near 100%, reaching 107% in FY25, and cash conversion rose from 94% to 98%.
The shares fell about 60% in a year in a perfect storm: 340B drug-rebate litigation that held back platform revenue, the SaaS apocalypse narrative, AIM capital flight after UK tax-relief cuts shrank the index from £75bn to £41bn, a summer 2026 cyber hack, and a first-ever guidance cut, from about $205m of revenue to $185m for FY27. James sees none of it damaging the franchise: 340B resolution should release deferred demand, and revenue is 100% US-based.
The 2021 Sentry/Agilum deal cost $400m, or 17.4x EBITDA, adding over $405m of goodwill and intangibles, so ROIC now screens in the mid-single digits versus the mid-20s before. James calls this an accounting illusion: adjusted, returns exceed 20% and the owner-earnings multiple is near the mid-teens. Management has repaid the acquisition debt, is cutting headcount by up to 20%, paused M&A, bought back $25m of stock in FY26 and kept a 32p dividend, returning $98.2m over five years.
At about 1,050p, Craneware has a $459m market cap and $448m EV, close to the $400m paid for Sentry/Agilum alone, against Bain Capital’s 2,650p approach in 2025, which management rejected without due diligence. An analyst model shows revenue growing at a 7.9% CAGR over FY27-FY29 and net profit at 37.5% as acquisition amortization halves to $11m. Catalysts include 340B resolution, 30%+ EBITDA margins and a possible US listing. Risks include the unquantified cyber liability, which James would provision at $50m, and founder succession.
Disclaimer
European Investing Summit 2026 was held from October 20-23, 2026. The content of this website is not an offer to sell or the solicitation of an offer to buy any security. The content is distributed for informational purposes only and should not be construed as investment advice or a recommendation to sell or buy any security or other investment, or undertake any investment strategy. There are no warranties, expressed or implied, as to the accuracy, completeness, or results obtained from any information set forth on this website. BeyondProxy’s officers, directors, employees, and/or contributing authors may have positions in and may, from time to time, make purchases or sales of the securities or other investments discussed or evaluated herein.
